Limits...
The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition - A Randomized Control Trial.

Szeto CC, Kwan BC, Chow KM, Cheng PM, Kwong VW, Choy AS, Law MC, Leung CB, Li PK - PLoS ONE (2015)

Bottom Line: There was no significant difference in residual renal function between the Groups.However, the effects on ultrafiltration and fluid accumulation disappear with time.The long term effect of low GDP solution requires further study.

View Article: PubMed Central - PubMed

Affiliation: Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

ABSTRACT

Background: Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients treated with low glucose degradation product (GDP) solution. The effects of low GDP solution on body fluid status and arterial pulse wave velocity (PWV) have not been studied.

Methods: We randomly assigned 68 incident PD patients to low GDP (Intervention Group) or conventional solutions (Control Group); 4 dropped off before they received the assigned treatment. Patients were followed for 52 weeks for changes in ultrafiltration, residual renal function, body fluid status and arterial PWV.

Result: After 52 weeks, Intervention Group had higher overhydration (3.1 ± 2.6 vs 1.9 ± 2.2 L, p = 0.045) and extracellular water volume (17.7 ± 3.9 vs 15.8 ± 3.1 L, p = 0.034) than Control Group. There was no significant difference in PWV between groups. There was no significant difference in residual renal function between the Groups. Intervention Group had lower ultrafiltration volume than Control Group at 4 weeks (0.45 ± .0.61 vs 0.90 ± 0.79 L/day, p = 0.013), but the difference became insignificant at later time points. Intervention Group had lower serum CRP levels than Control Group (4.17 ± 0.77 vs 4.91 ± 0.95 mg/dL, p < 0.0001).

Conclusion: Incident PD patients treated with low GDP solution have less severe systemic inflammation but trends of less ultrafiltration, and more fluid accumulation. However, the effects on ultrafiltration and fluid accumulation disappear with time. The long term effect of low GDP solution requires further study.

Trial registration: ClinicalTrials.gov NCT00966615.

No MeSH data available.


Related in: MedlinePlus

Consort diagram of the trial profile.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4625015&req=5

pone.0141425.g001: Consort diagram of the trial profile.

Mentions: During the recruitment period, we obtained consent from 68 patients, but 4 were excluded before treatment was started. Fig 1 depicts the Consort flow diagram that summarizes the trial profile. The baseline clinical characteristics of the 64 patients who received their assigned treatment are summarized in Table 1. In essence, the Intervention Group had more diabetic patients (64.5% vs 33.3%), tend to be older (62.9 vs 57.7 years), and had higher Charlson’s scores than the Control Group.


The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition - A Randomized Control Trial.

Szeto CC, Kwan BC, Chow KM, Cheng PM, Kwong VW, Choy AS, Law MC, Leung CB, Li PK - PLoS ONE (2015)

Consort diagram of the trial profile.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4625015&req=5

pone.0141425.g001: Consort diagram of the trial profile.
Mentions: During the recruitment period, we obtained consent from 68 patients, but 4 were excluded before treatment was started. Fig 1 depicts the Consort flow diagram that summarizes the trial profile. The baseline clinical characteristics of the 64 patients who received their assigned treatment are summarized in Table 1. In essence, the Intervention Group had more diabetic patients (64.5% vs 33.3%), tend to be older (62.9 vs 57.7 years), and had higher Charlson’s scores than the Control Group.

Bottom Line: There was no significant difference in residual renal function between the Groups.However, the effects on ultrafiltration and fluid accumulation disappear with time.The long term effect of low GDP solution requires further study.

View Article: PubMed Central - PubMed

Affiliation: Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

ABSTRACT

Background: Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients treated with low glucose degradation product (GDP) solution. The effects of low GDP solution on body fluid status and arterial pulse wave velocity (PWV) have not been studied.

Methods: We randomly assigned 68 incident PD patients to low GDP (Intervention Group) or conventional solutions (Control Group); 4 dropped off before they received the assigned treatment. Patients were followed for 52 weeks for changes in ultrafiltration, residual renal function, body fluid status and arterial PWV.

Result: After 52 weeks, Intervention Group had higher overhydration (3.1 ± 2.6 vs 1.9 ± 2.2 L, p = 0.045) and extracellular water volume (17.7 ± 3.9 vs 15.8 ± 3.1 L, p = 0.034) than Control Group. There was no significant difference in PWV between groups. There was no significant difference in residual renal function between the Groups. Intervention Group had lower ultrafiltration volume than Control Group at 4 weeks (0.45 ± .0.61 vs 0.90 ± 0.79 L/day, p = 0.013), but the difference became insignificant at later time points. Intervention Group had lower serum CRP levels than Control Group (4.17 ± 0.77 vs 4.91 ± 0.95 mg/dL, p < 0.0001).

Conclusion: Incident PD patients treated with low GDP solution have less severe systemic inflammation but trends of less ultrafiltration, and more fluid accumulation. However, the effects on ultrafiltration and fluid accumulation disappear with time. The long term effect of low GDP solution requires further study.

Trial registration: ClinicalTrials.gov NCT00966615.

No MeSH data available.


Related in: MedlinePlus